ANVS Annovis Bio Inc

via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.

“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”

“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”

“Our limited data in the three-month study we just did shows that our drug has better efficacy than the existing drugs on the market, at least in the short term. We have differentiated ourselves from other approaches with our mechanism of action for over 10 years, but the question is, does it improve cognition while being different? The exciting thing is that the FDA believes it's worth reproducing the data we have to prove that, in fact, it works. The FDA always wants you to have two studies, and this new pivotal Phase 3 studies will serve as a confirmation of the previous findings.”

Join IBN’s Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com